Document:

Ex-4.14 First Amendment to License Agreement

Exhibit 4.14

FIRST AMENDMENT TO LICENSE AGREEMENT

     This first amendment (the “Amendment”) to License Agreement is effective as of April 15,
2008 (the “Amendment Effective Date”), by on the one hand Protherics Medicines Development
Limited (“Protherics”), and on the other hand, Glenveigh Pharmaceuticals, LLC, Glenveigh
Research, LLC, C. David Adair, M.D., CDA Royalty Investors, LLC, and CDA Licensing
Administrators, LLC (collectively, each such entity and individual referred to individually as
a “Glenveigh Holder” and such entities and Dr. Adair, referred to collectively as “Glenveigh”).
Protherics and Glenveigh may be referred to herein individually as a “Party” and collectively
as the “Parties.”

RECITALS

     WHEREAS, the Parties entered into a License Agreement, dated December 7, 2006 (the
“License Agreement”); and

     WHEREAS, the Parties desire to amend the License Agreement to modify certain provisions
regarding milestone payments and equity holding periods.

     NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter
set forth, the Parties agree as follows:

     1. Amendment. The parties agree that the License Agreement shall be amended
as follows:

     A. Section 5.2 is hereby amended by deleting subsection 5.2(i) in its entirety and
replacing it with the following:

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	 
	 	 	 	 
	(i)

	 	Within one hundred twenty
(120) days after Protherics’
Successful Completion
	 	At the option of Protherics,
Protherics shall either (i) pay
Glenveigh Five Million U.S. Dollars
($5,000,000) or (ii) procure that
Glenveigh is issued 4,944,440.30
ordinary shares in the capital
of Protherics plc (“Additional
PTI Ordinary Shares”).* The number of
Additional PTI Ordinary Shares issued
to each of the Glenveigh Holders
shall be determined by instructions
delivered by Dr. Adair to Protherics
within 10 days of the Amendment
Effective Date.
	 
	 	 	 	 
	 

	 	 	 	*calculated as such number of shares
that could be purchased with Five
Million U.S. Dollars ($5,000,000) in
cash, with the PTI Ordinary Shares
being valued at the average
closing offer price of such shares
for the ninety (90) days
prior to Amendment Effective Date
and on the basis of the $/£ exchange
rate as taken from the London
Financial Times on the Amendment
Effective Date

 

 

     B. Section 5.9
shall be amended by deleting the entire text thereof and replacing it with the following:

     5.9 Equity Holding Period. A holding period was imposed on Glenveigh with respect to
any PTI Ordinary Shares granted to Glenveigh pursuant to Section 5.1.2. Such holding period shall
expire upon the Amendment Effective Date. During the holding period, Glenveigh agreed not to
dispose of or agree to dispose of, directly or indirectly, any such PTI Ordinary Shares or do
anything with the same or substantially the same economic effect (including a derivatives
transaction), without the prior written consent of Protherics plc. Following the Amendment
Effective Date, the PTI Ordinary Shares issued to Glenveigh pursuant to Section 5.1.2 will be
freely transferable under the rules of the London Stock Exchange, the Listing Rules of the UK
Financial Services Authority and English law, subject only to the restrictions contained in this
Agreement and as referred to in Article 202 of the Articles of Association of Protherics plc.

     C. Section 5.11
shall be amended by deleting the entire text thereof and replacing it with the following:

     5.11 Reserved.

     D. Section 6.2 shall be amended by deleting the strike-through text as indicated below.

     6.2 Patent Filing, Prosecution and Maintenance. Glenveigh shall own or Control
(as applicable) patents or patent applications within the Licensed Patents in the Territory.
During the term of this Agreement, Protherics shall be responsible for, and shall diligently
carry out and shall bear all costs (including attorneys’ fees) for the preparation, filing,
prosecution, maintenance and extensions(if any) of all patents or patent applications within
the Licensed Patents in the Territory. The filing, prosecution and maintenance of patents
and patent applications pursuant to this Section 6.2 shall be done through patent counsel
selected by Protherics and reasonably acceptable to Glenveigh. Protherics will keep
Glenveigh informed of all significant patent matters relating to the Licensed Patents, and
will give Glenveigh a reasonable opportunity to review and provide input on the prosecution
of applications within the Licensed Patents. Protherics shall have the right, after consultation with Glenveigh, and upon no less than thirty (30) days’
notice, to abandon any of the patents or patent applications within the Licensed Patents in
the Territory, In the event that Protherics decides to abandon any patent and/or patent
application within the Licensed Patents in the Territory, Glenveigh shall have the right to
continue the filing, prosecution or maintenance of any such patent or patent application
that Protherics wishes to abandon, at Glenveigh’s sole cost and expense.

     2. Additional Representations, Warranties and Covenants of Glenveigh. Each of the
Glenveigh Holders hereby represents and warrants, severally and not jointly, to Protherics, that:

          2.1. Authorization. Each Glenveigh Holder has full power and authority to enter into
this Amendment. This Amendment constitutes the valid and legally binding obligation of each
Glenveigh Holder, enforceable in accordance with its terms.

2

 

          2.2. Purchase Entirely for Own Account. This Amendment is made with Glenveigh Holder in reliance upon Glenveigh Holder’s representation to Protherics, which by Glenveigh
Holder’s execution of this Amendment, Glenveigh Holder hereby confirms, that the Additional PTI
Ordinary Shares to be acquired by Glenveigh will be acquired for investment for Glenveigh’s own
account, not as a nominee or agent, and not with a view to the resale or distribution in United States of any
part thereof, and that except for distributions by, to and among the Glenveigh Holders and their respective
members, Glenveigh Holder has no present intention of selling, granting any participation in, or
otherwise distributing the same. By executing this Amendment, Glenveigh Holder further represents that
Glenveigh Holder does not presently have any contract, undertaking, agreement or arrangement with any
person (other than as among the Glenveigh Holders and their respective members) to sell, transfer or
grant participations to such person or to any third person, with respect to any of the Additional
PTI Ordinary Shares. Glenveigh Holder has not been formed for the specific purpose of acquiring the
Additional PTI Ordinary Shares.

          2.3.
Disclosure of Information. Each Glenveigh Holder has received and reviewed the Disclosure Statement dated April 11, 2008 provided by Protherics and has the opportunity
to ask questions and receive answers from Protherics’s management about Protherics’s business,
management, financial affairs and the terms and conditions of the Additional PTI Ordinary Shares.

          2.4. No Registration of Additional PTI Ordinary Shares. Each Glenveigh Holder
acknowledges that the Additional PTI Ordinary Shares issued pursuant to Section 5.2 (i) have not
been registered under the United States Securities Act of 1933, as amended (the “Securities Act”)
or the securities laws of any state of the United States (“State Securities Laws”), and will be
issued to Glenveigh in a transaction not requiring registration under the Securities Act or any
State Securities Laws, and may not be offered, sold or otherwise transferred except in compliance
with the registration requirements of the Securities Act or any applicable State Securities Law,
pursuant to an exemption therefrom or in a transaction not subject thereto. Each certificate
representing Additional PTI Ordinary Shares will contain a legend substantially to the following
effect:

     THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE
UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE
REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE
UNITED STATES OR TO OR FOR THE ACCOUNT OF A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION
OR UNLESS THE TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT.

     Neither Protherics nor Protherics plc is under an obligation to register the sale, transfer
or other disposition of the Additional PTI Ordinary Shares by Glenveigh or on behalf of Glenveigh
under the Securities Act, or to take any other action necessary in order to make compliance with
an exemption from such registration available.

          2.5.
Accredited Investor. Each Glenveigh Holder is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

          2.6. No General Solicitation. No Glenveigh Holder, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including
through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in
connection with the offer and sale of the Additional PTI Ordinary Shares.

3

 

     2.7. Exculpation Among Glenveigh Holder. Each Glenveigh Holder acknowledges that it is not relying upon any person, firm or corporation, other than Protherics and its
officers and directors, in making its investment or decision to invest in Protherics. Each Glenveigh Holder
agrees that no Glenveigh Holder nor the respective controlling persons, officers, directors, partners,
agents, or employees of any Glenveigh Holder shall be liable to any other Glenveigh Holder for any action
heretofore or hereafter taken or omitted to be taken by any of them in connection with the
purchase of the Additional PTI Ordinary Shares.

     2.8. Residence. If Glenveigh Holder is an individual, then Glenveigh Holder resides in the state or province identified in the address of Glenveigh Holder set forth in the
preamble of the License Agreement; if Glenveigh Holder is a partnership, corporation, limited liability
company or other entity, then the office or offices of Glenveigh Holder in which its principal place of
business is located is at the address or addresses of Glenveigh Holder set forth in the preamble of the License
Agreement.

     3. Protherics Representations, Warranties and Covenants. Protherics represents,
warrants and covenants to Glenveigh as follows:

          3.1. Authorization. Protherics has full power and authority to enter into this
Amendment. This Amendment constitutes the valid and legally binding obligation of Protherics,
enforceable in accordance with its terms.

          3.2 PTI Ordinary Shares and Additional PTI Ordinary Shares. Following the Amendment
Effective Date, the PTI Ordinary Shares issued to Glenveigh pursuant to Section 5.1.2 and any
Additional PTI Ordinary Shares that may be issued to Glenveigh pursuant to Section 5.2 will be
freely transferable under the rules of the London Stock Exchange, the Listing Rules of the UK
Financial Services Authority and English law, subject only to the restrictions contained in
Section 2.4 of this Amendment and as referred to in Article 202 of the Articles of Association of
Protherics pls. Subject to applicable law, Protherics agrees and covenants to cooperate fully with
Glenveigh and Protherics’ transfer agent (including removing of any legends as appropriate) in any
future sales by Glenveigh of the PTI Ordinary Shares and any Additional PTI Ordinary Shares that
are lawfully made under applicable securities laws and exemptions, including but not limited to,
Regulation S promulgated under the Securities Act.

     4. Amendment and Ratification. The License Agreement is hereby amended in accordance
with the foregoing provisions of this Amendment. The License Agreement, as amended as
provided herein, is hereby ratified and shall remain in full force and effect.

     5. Defined Terms. Capitalized terms used in this Amendment shall have the same
meanings as in the License Agreement unless otherwise defined herein.

     6. Counterparts. This Amendment may be executed in counterparts by original or
facsimile signature, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

[SIGNATURES ON FOLLOWING PAGE]

4

 

     IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed by their duly
authorized representative as of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 
	GLENVEIGH PHARMACEUTICALS, LLC	 	PROTHERICS MEDICINES

DEVELOPMENT LIMITED	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ C. David Adair, M.D.
 	 	 
	 	By:
	 	/s/ Saul Komisar
	 	 
	 

	 	 

Name: C. David Adair, M.D.
	 	 	 	 	 	 

Name: Saul Komisar	 	 
	 

	 	Title:   Chairman
	 	 	 	 	 	Title: President/ Director	 	 

	 	 	 	 	 
	GLENVEIGH RESEARCH, LLC

 	 	 
	By:  	/s/ C. David Adair, M.D.
 	 	 
	 	Name:  	C. David Adair, M.D. 	 	 
	 	Title:  	Chief Manager 	 	 
	 
	C. DAVID ADAIR, M.D.

 	 	 
	By:  	/s/ C. David Adair, M.D.
 	 	 
	 	Name:  	C. David Adair, M.D. 	 	 
	 	Title:  	 	 	 
	 
	CDA ROYALTY INVESTORS, LLC

 	 	 
	By:  	/s/ William R. Russell
 	 	 
	 	Name:  	William R. Russell 	 	 
	 	Title:  	President	 	 
	 
	CDA LICENSING ADMINISTRATORS, LLC 

 	 	 
	By:  	/s/ C. David Adair, M.D.
 	 	 
	 	Name:  	C. David Adair, M.D. 	 	 
	 	Title:  	Manager 	 	 
	 

5EX-4.15 Supply and Distribution Agreement

Exhibit
4.15

1 March 2006

PROTHERICS MOLECULAR DESIGN

LIMITED

and

IDIS LIMITED

SUPPLY AND DISTRIBUTION AGREEMENT

Page  1 of  33

 

1 March 2006

PARTIES

	(1)	 	PROTHERICS MOLECULAR DESIGN LIMITED (Company Number
01939643, whose registered office is at The Heath Business and
Technical Park, Runcorn, Cheshire WA7 4QF
	 
	 	 	(“the Manufacturer”); and
	 
	(2)	 	IDIS LIMITED (Company Number 2143039), whose registered office is at
IDIS House, Churchfield Road, Weybridge, Surrey. KT13 8DB
	 
	 	 	(“IDIS”).

INTRODUCTION

	A)	 	The Manufacturer wishes to supply the Product (as defined below) in the
Territory (as also defined below) on a Named Patient Supply basis through
an entity that is qualified so to distribute it.
	 
	B)	 	IDIS is qualified to distribute the Product on a Named Patient Supply basis
throughout the Territory and wishes to act as the Manufacturer’s distributor of
the Product.
	 
	C)	 	The Manufacturer hereby appoints IDIS as its exclusive distributor of the
Product in the Territory on a Named Patient Supply basis on the terms, and
subject to the conditions, of this Agreement, which appointment IDIS accepts.

THE PARTIES AGREE AS FOLLOWS

	1.	 	Definitions and interpretation
	 
	1.1.	 	In this Agreement the following words have the following meanings unless
the context otherwise requires:
	 
	 	 	“Business Day” means a day, other than Saturday or Sunday on which
banks are open in the City of London for the transaction of normal banking
business;
	 
	 	 	“Commencement Date” means the date of signature of this Agreement by
both parties;
	 
	 	 	“Complaints Procedure” means IDIS’s procedure for handling and
responding to complaints, and for advising the Manufacturer thereof, as the

Page  2 of  33

 

	 	 	same may be amended with the agreement of the Manufacturer from time to
time, the current version of which is at Schedule 6;
	 
	 	 	“Fax Address” means, in respect of a party, the fax number of that party
specified in Schedule 4;
	 
	 	 	“Force Majeure” means any circumstances beyond the reasonable control of
a party (including, without limitation, any strike, lock-out or other form of
industrial action) which prevents that party from complying with any of its
obligations under this Agreement;
	 
	 	 	“Initial Period” means the period of three years commencing on the
Commencement Date;
	 
	 	 	“Intellectual Property” means any patent, copyright, database right, right in
any design, registered design, trade mark, trade name or other industrial or
intellectual property right, whether or not registered, which may subsist in the
Territory, now or in the future, all renewals and extensions thereof and any
applications for any of the foregoing, together with the right to make such
applications;
	 
	 	 	“Marketing Authorisation” means a licence granted pursuant to section 5(1)
of the Regulation lawfully to place on the market, or distribute by way of
wholesale dealing, a Relevant Medicinal Product pursuant to section 3(1) of
the Regulation, and all equivalent or similar licences granted in any part of
the Territory;
	 
	 	 	“Named Patient Supply” means the lawful placing on the market or
distribution by way of wholesale dealing of a Relevant Medical Product for
which no Marketing Authorisation is in force in the part of the Territory or
where no such licensed product is available in the part of the Territory in
which such Relevant Medicinal Product is placed on the market or distributed
by way of wholesale dealing at the time of such placing on the market or
distribution;
	 
	 	 	“Normal Business Hours” means the hours of 8 a.m. and 6 p.m. inclusive on
a Business Day;
	 
	 	 	“Out of Hours” means any time other than during Normal Business Hours;
	 
	 	 	“Out of Hours Policy” means IDIS’s procedure for supplying the Product Out
of Hours, the current version of which is attached at Schedule 5;
	 
	 	 	“Prices” means the price to be paid by IDIS to the Manufacturer for the
Product set out in Schedule 1, as may be varied in accordance with clause
4.9;

Page  3 of  33

 

	 	 	“Product” means the pharmaceutical product, Voraxaze TM ;
	 
	 	 	“Recall Procedure” means IDIS’s procedure for effecting recalls of the
Product, as the same may be amended from time to time, the current version
of which is at Schedule 8;
	 
	 	 	“Regulation” means the Medicines for Human Use (Marketing Authorisations
etc.) Regulations 1994;
	 
	 	 	“Relevant Medicinal Product” means a pharmaceutical product so classified
by the Regulation, together with any pharmaceutical product similarly
classified in any part of the Territory, the placing on the market or distribution
by way of wholesale dealing or otherwise of which is similarly restricted;
	 
	 	 	“Restricted Information” means any information which is disclosed to IDIS by
or on behalf of the Manufacturer under or in connection with this Agreement
or IDIS’s distribution of the Product (whether orally or in writing, and whether
or not such information is expressly stated to be confidential or marked as
such);
	 
	 	 	“Service Address” means, in respect of a party, the address for service of
that party, as specified in Schedule 4;
	 
	 	 	“Technical Agreement” means the agreement between the parties relevant to
the Product and the handling, transport and storage thereof, a copy of which
is at Schedule 7;
	 
	 	 	“Term” means the term of this Agreement;
	 
	 	 	“Terms and Conditions” means the terms and conditions contained in
Schedule 3;
	 
	 	 	“Territory” means those listed in Schedule 9 of this agreement.
	 
	 	 	“Trade Mark” means the trade mark specified in Schedule 2 and such other
trade marks as the Manufacturer may notify to IDIS in writing from time to
time.
	 
	1.2.	 	Headings to the clauses of and Schedules to this Agreement are for
convenience only and shall not affect its interpretation.
	 
	1.3.	 	Words in this Agreement importing the singular include the plural and vice
versa.
	 
	1.4.	 	References in this Agreement to clauses and Schedules are to the clauses of
and Schedules to this Agreement.

Page 4 of 33

 

	1.5.	 	References in this Agreement to a party, or the parties, are to a party, or the
parties, to this Agreement.
	 
	1.6.	 	The Schedules are deemed to be incorporated in, and form part of, this
Agreement and the term “Agreement” shall be construed accordingly.
	 
	1.7.	 	References in this Agreement to a person include any person, individual,
company, firm, corporation, government, state or agency of a state or any
undertaking (whether or not having separate legal personality and
irrespective of the jurisdiction in or under the law of which it was incorporated
or exists).
	 
	1.8.	 	References in this Agreement to a statute or statutory instrument or any of
their provisions is to be construed as a reference to that statute or statutory
instrument or such provisions the same may have been or may from time to
time hereafter be amended or re-enacted.
	 
	2.	 	Appointment
	 
	2.1.	 	The Manufacturer shall sell the Product to IDIS on the terms and subject to
the conditions of this Agreement.
	 
	2.2.	 	During the Term, the Manufacturer shall not actively market or sell the
Product to any person other than IDIS for such person to sell the Product in
the Territory on a Named Patient Supply basis, without first obtaining IDIS’s
express written consent.
	 
	2.3.	 	Nothing in clauses 2.1 or 2.2 shall restrict the Manufacturer in, or prevent the
Manufacturer from, passively selling the Product in response to any
unsolicited orders therefor.
	 
	2.4.	 	IDIS shall not, unless otherwise approved in writing by the Manufacturer and
while this Agreement is in force:

	 	2.4.1.	 	manufacture any goods that compete with the Product; or

	 
	 	2.4.2.	 	obtain supplies of the Product other than from the Manufacturer.

	3.	 	Term
	 
	3.1.	 	This Agreement shall commence on the Commencement Date and shall
continue in force (subject to clauses 3.2, 3.3, 10 and 13.3) for the Initial
Period, at the end of which this Agreement shall terminate.
	 
	3.2.	 	The Manufacturer may terminate this Agreement, either in total or in respect
of one or more parts of the Territory, by giving not less than ninety days’

Page 5 of 33

 

	 	 	written notice to IDIS to that effect and may give notice pursuant to this
clause 3.2 on any number of occasions during the Term.
	 
	3.3.	 	This Agreement shall terminate automatically in respect of any given part of
the Territory upon the grant to the Manufacturer of a Marketing Authorisation
for the Product in that part, whereafter the Territory shall no longer include
such part.
	 
	4.	 	Supply of the Product
	 
	4.1.	 	Every three months of the Term, IDIS shall submit to the Manufacturer or, if the Manufacturer
so directs, such third party as may undertake the manufacture of the Product in a form suitable for
sale on a Named Patient Supply basis as the Manufacturer may notify to IDIS from time to time,
monthly, rolling, non-binding, written forecasts of the quantities of the Product IDIS estimates it
will sell during the subsequent twelve months, the first such forecast to be given within 10
Business Days following the Commencement Date, and shall revise any such forecast promptly
following becoming aware of any change thereto or error therein.
	 
	4.2.	 	With each forecast submitted pursuant to clause 4.1, IDIS shall, in accordance with the Terms
and Conditions, submit to the Manufacturer or, if the Manufacturer so directs, to such third party
as may undertake the manufacture of the Product in a form suitable for sale on a Named Patient
Supply basis and as the Manufacturer may notify to IDIS from time to time, a written binding order
for the quantities of the Product it will purchase during the three months period commencing on the
date one month following the date of such order, each such order to be for a quantity of the
Product no greater than ten per cent. more or less than the quantity which IDIS forecast it would
require in that period in the last forecast given by IDIS hereunder before submitting such order.
	 
	4.3.	 	The Manufacturer shall supply, or shall cause such third party as may undertake the
manufacture of the Product in a form suitable for sale on a Named Patient Supply basis to supply,
the Product ordered by IDIS pursuant to clause 4.2 to IDIS in accordance with the Terms and
Conditions and IDIS shall pay for the same in accordance with, and otherwise comply with, the Terms
and Conditions.
	 
	4.4.	 	IDIS shall apply for, and shall use all reasonable endeavours to obtain and maintain, all
import permits, consents and licences as may be required for its import of the Product into any
country or territory in the course of, or following, the delivery thereof to IDIS.
	 
	4.5.	 	In the event that any delivery of the Product to IDIS hereunder is prevented or delayed as a
result of IDIS not complying with its obligations pursuant to clause 4.4 or for any other reason
not having all such permits, consents and

Page 6 of 33

 

	 	 	licences as are referred to therein, the Manufacturer shall have no liability for such
prevention or delay.
	 
	4.6.	 	The Manufacturer shall, or shall cause such third party as may undertake the manufacture of
the Product in a form suitable for sale on a Named Patient Supply basis to, notify IDIS as soon as
reasonably practicable of any problem it, or such third party, shall experience or reasonably
anticipates experiencing with the supply of the Product to IDIS in accordance herewith, provide
IDIS with such details of the cause thereof as IDIS may reasonably require and update IDIS at least
once a week of the status of such problem until normal supplies are resumed, if they are in fact
disrupted.
	 
	4.7.	 	The Product shall be sold to IDIS at the Prices.
	 
	4.8.	 	IDIS will charge the Manufacturer a monthly fee, as specified in Schedule 1, for the provision
of the Out of Hours Service.
	 
	4.9.	 	The Prices may be varied by the Manufacturer by giving not less than 60 days’ notice to IDIS
but nothing in this clause shall give the Manufacturer the right to vary prices in respect of
orders of the Product placed by IDIS prior to the date of receipt of any notice of variation.
	 
	4.10.	 	The Prices are exclusive of any applicable value added or any other sales tax due in respect
of the sale of the Product to IDIS for which IDIS shall be additionally liable and for which the
Manufacturer shall invoice IDIS.
	 
	4.11.	 	In the event of a conflict between the terms of this Agreement and the Terms and Conditions,
the former shall prevail.
	 
	5.	 	Rights and duties of IDIS
	 
	5.1.	 	During the Term, IDIS shall:

	 	5.1.1.	 	sell the Product on a Named Patient Supply basis in the Territory, shall deal with,
or otherwise dispose of, the Product only by way of such sales and shall adhere to the Out
of Hours Policy in respect of such sales of, and requests for, the Product made Out of
Hours;
	 
	 	5.1.2.	 	without prejudice to the generality of clause 5.3, ensure that all Product sold by
IDIS, and IDIS’s sales thereof, comply with all applicable regulations and statutory or
other requirements in the Territory from time to time relevant to it or its sale on a Named
Patient Supply basis and, in particular but without limitation, with all safety regulations
and all regulations relating to the storage or distribution of the Product, and inform the
Manufacturer in the event of IDIS becoming aware of any relevant new such requirements
likely to come into force in the Territory or which so come into force;

Page 7 of 33

 

	 	5.1.3.	 	without prejudice to the generality of clause 5.1.2, ensure that during the Term and
throughout the Territory, IDIS is and remains entitled to sell the Product on a Named Patient
Supply basis;
	 
	 	5.1.4.	 	use all reasonable endeavours lawfully to maximise its sales of the Product to the
extent not restricted by law or otherwise by this Agreement, and not do anything which may
hinder or interfere with such sales, including without limitation by failing to satisfy any
order it receives for the Product on a Named Patient Supply basis without good reason;
	 
	 	5.1.5.	 	develop and maintain contacts with actual and potential customers for the Product;
	 
	 	5.1.6.	 	be entitled to describe itself as the Manufacturer’s authorised distributor of the
Product in the Territory and to describe itself as such on all letters, invoices and other
commercial documents;
	 
	 	5.1.7.	 	in all correspondence and all dealings relating directly or indirectly to the Product
clearly indicate that it is acting as principal and not represent itself as the agent of the
Manufacturer;
	 
	 	5.1.8.	 	unless otherwise prohibited by the relevant legal requirements, maintain at all times
a minimum stock of the Product (such minimum to be determined by IDIS but to be no less than
any quantity that the Manufacturer may specify from time to time) as IDIS shall require to
meet the demand therefor from third parties;
	 
	 	5.1.9.	 	supply the Manufacturer monthly with a written inventory of such stock of the Product
as it has;
	 
	 	5.1.10.	 	follow all technical instructions given by the Manufacturer relating to the Product
or its storage or handling and instructions to customers on such matters;
	 
	 	5.1.11.	 	promptly inform the Manufacturer of all customer complaints, requirements and
suggestions regarding the Product in accordance with the Complaints Procedure, and of any
other information which comes to its knowledge which may prejudice sales of the Product
(whether or not on a Named Patient Supply basis) or affect any Marketing Authorisation which
may be granted therefor, or such grant, or the maintenance thereof;
	 
	 	5.1.12.	 	promptly inform the Manufacturer and all relevant regulatory authorities of any
adverse reactions to the Product or other matters of an adverse nature reported to it or of
which it otherwise becomes

Page 8 of 33

 

	 	 	 	aware and, subject to clause 6.3, comply with all such regulatory authorities’ requirements with respect
to such adverse reactions or other matters;
	 
	 	5.1.13.	 	if IDIS recalls any of the Product, promptly notify all customers who have purchased from IDIS
any quantity of the Product to which such recall does or may apply; implement the recall
and arrange the return of the recalled Product to the Manufacturer; fully inform the Manufacture
and keep the Manufacturer fully informed (including without limitation by providing such information
concerning the recall as the Manufacturer may request when requested), of the recall’s progress; and
otherwise comply with the Recall Procedure in implementing the recall;
	 
	 	5.1.14.	 	if IDIS wishes to recall any of the Product, without prejudice to clause 5.1.13, promptly inform
the Manufacturer in writing of its wish and the urgency of undertaking that recall, and promptly
provide details of the relevant problem with the Product concerned, and its batch number, to the
Manufacturer together with details of any alternative Product that is available for sale by IDIS;
	 
	 	5.1.15.	 	not affect any recall of any of the Product unless the Manufacturer has first decided
that it should be recalled;
	 
	 	5.1.16.	 	notify the Manufacturer promptly of any matters which are likely to be of interest, use or
benefit to the Manufacturer in relation to sales of the Product (whether or not on a Named Patient
Supply basis), and in particular matters relating to any information, recommendations or opinions
expressed by customers of IDIS relating to the Product;
	 
	 	5.1.17.	 	immediately notify the Manufacturer of any improper or wrongful use in the Territory of
the Trade Mark or any emblems, designs, models and other similar Intellectual Property of the Manufacturer which come to its notice;
	 
	 	5.1.18.	 	use every effort to safeguard the Intellectual Property and other interests of the
Manufacturer relevant to the Product and, at the request of the Manufacturer, assist the Manufacturer in defending the same;
	 
	 	5.1.19.	 	keep in its premises full, proper and up-to-date books of account and records showing
clearly all enquiries, quotations, transactions and proceedings relating to IDIS’s sales of the
Product and allow the authorised representatives of the Manufacturer, or their duly appointed
agents, at all reasonable times during usual office hours to have access to IDIS’s premises for
the purpose of inspecting such books and records;

Page 9 of 33

 

	 	5.1.20.	 	from time to time upon the request of the Manufacturer supply to the Manufacturer
reports, returns and other information relating to IDIS’s sales of the Product;
	 
	 	5.1.21.	 	insure at its own cost with a reputable insurance company all stocks of the Product
which it may hold against all risks to at least the full replacement value of those stocks
and produce at the Manufacturer’s request particulars of that insurance and a receipt for
the appropriate premium;
	 
	 	5.1.22.	 	inform the Manufacturer immediately of any changes in IDIS’s organisation, staff or
methods of doing business which may affect the performance of its obligations under this
Agreement; and
	 
	 	5.1.23.	 	inform the Manufacturer within five Business Days of the start of each month of the
prices at which IDIS has sold the Product during the previous month in each country or
territory of the Territory.

	5.2.	 	IDIS shall not directly or indirectly, personally or through an agent, intermediary or
subsidiary:

	 	5.2.1.	 	incur any liability or assume any obligation of any kind on behalf of the
Manufacturer or in any way pledge or purport to pledge the Manufacturer’s credit or accept
or purport to accept any order to make any contract binding upon the Manufacturer;
	 
	 	5.2.2.	 	give, or purport to give, any condition, warranty, representation, promise or
guarantee, implied or express, on behalf of the Manufacturer;
	 
	 	5.2.3.	 	make any promises or guarantees in respect of the Product save as expressly agreed in
writing by the Manufacturer;
	 
	 	5.2.4.	 	misrepresent the Manufacturer’s descriptions or indications for use of the Product or
give, in any manner or format, any scientific information or information regarding the
Product’s characteristics to any person, unless the same has first been approved by the
Manufacturer;
	 
	 	5.2.5.	 	distribute during the Term any goods of the same description as, or which compete
with, the Product; or
	 
	 	5.2.6.	 	remove any of the Product from its packaging or otherwise damage or tamper or
interfere with that packaging or its contents (including without limitation, the Product)
without the Manufacturer’s prior written approval.

Page 10 of 33

 

	5.3.	 	IDIS shall at all times in connection with its purchase, storage, handling or sale of the
Product, or otherwise in performing its obligations hereunder, comply with all applicable laws
and regulations, and conduct itself, and undertake its obligations hereunder, with reasonable
skill, care and attention.
	 
	5.4.	 	Without prejudice to the generality of the foregoing, IDIS shall comply with the
Technical Agreement in all respects.
	 
	5.5.	 	IDIS acknowledges that no Marketing Authorisation has been granted for the Product in any
part of the Territory and that it can only sell the Product on a Named Patient Supply basis.
	 
	6.	 	Rights and duties of the Manufacturer
	 
	6.1.	 	The Manufacturer shall, from time to time, endeavour to answer as soon as practicable any
technical enquiries concerning the Product which are made by IDIS.
	 
	6.2.	 	If the Manufacturer decides to recall any Product, the Manufacturer shall immediately
notify IDIS by telephone, fax or email with confirmation in writing of the recall and its
urgency and provide details of the relevant problem with the Product concerned, the batch
number of the Product concerned and the details of any alternative Product that is available.
Upon the decision of the Manufacturer to recall any of the Product, IDIS shall implement its
recall as required by clause 5.1.13, and the Manufacturer shall credit IDIS the cost of the
recalled returned Product and any additional reasonable costs incurred by IDIS in undertaking
such recall.
	 
	6.3.	 	In the event IDIS notifies the Manufacturer of a reported adverse reaction by a customer
to the Product, the Manufacturer will henceforth assume the conduct of, and determine whether
and how to undertake, any actions that may be required in respect of the adverse reaction and
shall confirm to IDIS in writing that it has done so.
	 
	6.4.	 	The Manufacturer shall upon sixty days’ notice to IDIS be entitled to make changes in the
formulation and/or composition of the Product.
	 
	7.	 	Warranties
	 
	7.1.	 	The Manufacturer accepts responsibility for the manufacture of the Product and its
packaging and labelling and warrants to IDIS that at the time of its delivery to IDIS all Product so delivered shall be of merchantable quality and free
from defects in composition or formulation.
	 
	7.2.	 	The Manufacturer warrants to IDIS in respect of such Product as is delivered to IDIS
hereunder, that at the time of its delivery to IDIS:

Page 11 of 33

 

	 	7.2.1.	 	the Manufacturer will have title to such Product; and
	 
	 	7.2.2.	 	such Product shall conform to its description and specification.

	7.3.	 	IDIS warrants to the Manufacturer that IDIS has, and will maintain and retain, the requisite
resources (including, but not limited to, personnel and premises) to perform its obligations
pursuant to this Agreement, and will so perform them.
	 
	7.4.	 	Without prejudice to the generality of clause 7.3, IDIS warrants to the Manufacturer that it
is licensed, and throughout the Term will remain licensed, to sell the Product on a Named Patient
Supply basis throughout the Territory.
	 
	8.	 	Indemnity
	 
	8.1.	 	The Manufacturer shall now and at all times in the future indemnify IDIS from and against all
loss, damage and expense awarded by a court of competent jurisdiction resulting from all claims,
demands, actions, causes of action and judgments of any kind arising out of or attributable to:

	 	8.1.1.	 	the use of the Product by a third party; or
	 
	 	8.1.2.	 	the sale of the Product on a Named Patient Supply basis in the Territory;

		 	except where the same arises out of or is attributable to the negligence or default,
including without limitation, breach of this Agreement, of IDIS.

	 
	8.2.	 	The indemnity in clause 8.1 shall not apply where any relevant claim, demand, action, cause of
action or judgment arises out of or is attributable to any mark or method of packaging or get up on
or of the Product or any written material or directions relating to the Product applied, used or
given by IDIS otherwise than as directed by the Manufacturer.
	 
	8.3.	 	IDIS shall now and at all times in the future indemnify and hold harmless the Manufacturer
from and against all loss, damage and expense awarded by a court of competent jurisdiction
resulting from any demands, actions, causes of action or judgments of any kind arising out of or
attributable to IDIS’s breach of clauses 7.3 or 7.4 or otherwise out of or attributable to its
breach of this Agreement.
	 
	8.4.	 	The indemnities contained in clauses 8.1 and 8.3 above shall be conditional in each case upon
prompt written notice of any relevant claim, demand, action, cause of action or judgment being made
by the indemnified party to the indemnifying party; the indemnified party giving the indemnifying
party conduct of the defence or settlement of any such claim, at its cost and

Page 12 of 33

 

	 	 	expense, and not compromising nor making any statement prejudicial to such defence or
settlement; and the indemnified party providing the indemnified party with all reasonable
assistance, at the indemnifying party’s cost and expense, in such conduct.
	 
	9.	 	Intellectual property
	 
	9.1.	 	The Manufacturer hereby licenses IDIS non-exclusively to use the Trade Mark in the Territory
on, or in relation to, the Product for the purpose only of performing its obligations under this
Agreement but IDIS shall not sub-license, or purport to sub-license, any other person to make any
use of the Trade Mark.
	 
	9.2.	 	The Manufacturer hereby licenses IDIS non-exclusively under its rights in and to the Product
for the term of this Agreement, only to sell the Product in accordance with this Agreement and to
import and export the Product solely for such purpose or otherwise to comply with its express
obligations herein, but IDIS shall not sub-license, or purport to sub-license, any other person
thereunder.
	 
	9.3.	 	IDIS shall ensure that each reference to, and use of, the Trade Mark by IDIS is in a manner
from time to time approved by the Manufacturer and accompanied by an acknowledgement, in a form
approved by the Manufacturer, that the same is a trade mark (or registered trade mark) of the
Manufacturer.
	 
	9.4.	 	IDIS shall not:

	 	9.4.1.	 	make any modifications to the Product or its packaging or obscure, deface or
over-sticker any part of any of that packaging;
	 
	 	9.4.2.	 	alter, remove, obscure, deface, over-sticker or tamper with the Trade Mark, or any
numbers or other means of identification used on, or in relation to, the Product;
	 
	 	9.4.3.	 	use the Trade Mark in any way which might prejudice its distinctiveness or validity
or the goodwill of the Manufacturer therein;
	 
	 	9.4.4.	 	use in relation to the Product any trade marks other than the Trade Mark without
obtaining the prior written consent of the Manufacturer; or
	 
	 	9.4.5.	 	use any trade marks or trade names so resembling any trade mark or trade names of
the Manufacturer as to be likely to cause confusion or deception.

	9.5.	 	Except as provided in clauses 9.1 and 9.2, IDIS shall have no rights in respect of any
Intellectual Property of the Manufacturer or of the goodwill

Page 13 of 33

 

	 	 	associated with the Trade Mark or any other trade marks or trade names of the
Manufacturer or otherwise to, or in respect of the Product, and IDIS hereby acknowledges
that, except as expressly provided in this Agreement, it shall not acquire any rights in
respect of any such trade marks or trade names and that all such rights and goodwill are,
and shall remain, vested in the Manufacturer, whether or not such goodwill is generated by
IDIS’s use of such trade marks or trade names, and that IDIS will hold the same on trust for
the Manufacturer and assign the same to the Manufacturer upon request and at any time,
whether before or after the termination of this Agreement.

	9.6.	 	IDIS shall, at the expense of the Manufacturer, take all such steps as the Manufacturer may
reasonably require to assist the Manufacturer in maintaining the validity and enforceability of the
Intellectual Property of the Manufacturer in relation to the Product or the Manufacturer’s rights
therein or thereto.
	 
	9.7.	 	IDIS shall, at the request of the Manufacturer, execute such licences in respect of the use of
the Trade Mark or of the Manufacturer’s Intellectual Property subsisting in the Product as the
Manufacturer may reasonably require, provided that the provisions of any licences shall not be more
onerous or restrictive than the provisions of this Agreement.
	 
	9.8.	 	Without prejudice to the right of IDIS or any third party to challenge the validity of any
Intellectual Property of the Manufacturer, IDIS shall not do or authorise any third party to do any
act which would or might invalidate or be inconsistent with any Intellectual Property of the
Manufacturer in relation to the Product or the Manufacturer’s rights therein or thereto, and shall
not omit, or authorise any third party to omit, to do any act which, by its omission, would have
that effect.
	 
	9.9.	 	IDIS shall promptly and fully notify the Manufacturer of any actual, threatened or suspected
infringement of any Intellectual Property of the Manufacturer relating to the Product which comes
to IDIS’s notice, and of any claim by any third party so coming to its notice that the importation
of the Product into, or export out of, any part of the Territory, or its sale in any part of the
Territory, infringes any rights of any other person, and IDIS shall, at the request and expense of
the Manufacturer, do all such things as may be reasonably required to assist the Manufacturer in
taking or resisting any proceedings in relation to any such infringement or claim by or against any
third party.
	 
	9.10.	 	The application of section 30 of the Trade Marks Act 1994 and of all equivalent provisions of
all relevant legislation in each jurisdiction in which the Trade Mark is registered are, to the
fullest extent permissible by law, hereby excluded.
	 
	10.	 	Termination

Page 14 of 33

 

	10.1.	 	Either party shall have the right to terminate this Agreement immediately by notice to the
other if:

	 	10.1.1.	 	the other party commits any material breach of any of the provisions of this
Agreement and, in the case of a breach capable of remedy, that party fails to remedy such
breach within 30 days after receipt of a notice giving full particulars of the breach and
requiring it to be remedied;
	 
	 	10.1.2.	 	an encumbrancer takes possession of, or a receiver is appointed over, any of the
property or assets of that other party;
	 
	 	10.1.3.	 	the other party becomes subject to an administration order or makes a voluntary
arrangement with its creditors within the meaning of the Insolvency Act 1986;
	 
	 	10.1.4.	 	the other party goes into liquidation (except for the purposes of amalgamation or
reconstruction and in such manner that the company resulting therefrom effectively agrees to
be bound by or assume the obligations imposed on that other party under this Agreement);
	 
	 	10.1.5.	 	any proceedings analogous to those referred to in clauses
10.1.2 to 10.1.4 occur in
relation to the other party or its assets in accordance with the jurisdiction to which the
other party or its assets are subject;
	 
	 	10.1.6.	 	the other party ceases, or threatens to cease to carry on business; or
	 
	 	10.1.7.	 	pursuant to clause 13.3.

	10.2.	 	For the purposes of clause 10.1.1 a breach shall be considered capable of remedy if the party
in breach can comply with the provision in question in all respects within the 30 days period
mentioned in that clause, save as to the time of performance (provided that time of performance is
not of the essence).
	 
	10.3.	 	Any waiver by either party of a breach of any provision of this Agreement shall not be
considered as a waiver of any subsequent breach of the same or any other provision of this
Agreement.
	 
	10.4.	 	The rights to terminate this Agreement given by this clause shall be without prejudice to any
other right or remedy of either party in respect of the breach concerned (if any) or any other
breach.
	 
	11.	 	Consequences of termination
	 
	11.1.	 	Upon termination of this Agreement IDIS shall:

Page 15 of 33

 

	 	11.1.1.	 	save as otherwise agreed below, immediately cease to make use of the Trade Mark;
	 
	 	11.1.2.	 	at the request of the Manufacturer and at the Manufacturer’s expense and option,
return to the Manufacturer or destroy any Restricted Information in its possession or under
its control; and
	 
	 	11.1.3.	 	in the event that such termination occurred pursuant to notice given by IDIS
pursuant to clause 10.1.1 or 13.3, be entitled to complete all orders for the Product placed
by its customers prior to the date of termination of this Agreement, but no others, provided
that the Manufacturer shall be under no obligation to supply any Product to IDIS not ordered
hereunder prior such date and that IDIS otherwise continues to comply with its obligations
hereunder.

	11.2.	 	In the event of termination of this Agreement by IDIS pursuant to clauses 10.1.1 or 13.3:

	 	11.2.1.	 	subject to clause 11.1.3, IDIS shall, if the Manufacturer so requests within 10
Business Days of the date of termination of this Agreement, sell at cost all or any part of
the stocks of the Product then held by IDIS to the Manufacturer, provided that IDIS shall be
responsible for arranging, and for the cost of, their transportation and insurance during
transit, and shall ensure that all such Product is received by the Manufacturer at such
location as it may designate in perfect condition; and
	 
	 	11.2.2.	 	IDIS shall be entitled to sell all remaining stocks of the Product that the
Manufacturer does not wish to repurchase under clause 11.2.1 and for those purposes and to
that extent, the provisions of this Agreement shall continue in full force and effect.

	11.3.	 	Without prejudice to clause 11.2, in the event of termination of this Agreement by IDIS
pursuant to clause 10.1.1, IDIS may at its option elect to return to the Manufacturer all or part
of any stocks of the Product held by IDIS at the date of termination and the Manufacturer shall be
responsible for arranging, and for the cost of, their transportation and insurance during transit.
	 
	11.4.	 	Upon the termination of this Agreement IDIS shall have no claim against the Manufacturer for
loss of distribution rights, goodwill or other similar loss.
	 
	11.5.	 	Clauses 7.1, 7.2, 8, 9.5, 11 and 12 shall survive termination of this Agreement.
	 
	12.	 	Confidential information

Page 16 of 33

 

	12.1.	 	Except as provided by clauses 12.2 and 12.3, IDIS shall at all times during the continuance
of this Agreement and after its termination:

	 	12.1.1.	 	keep all Restricted Information confidential and accordingly not to disclose any
Restricted Information to any other person or permit any other person so to do; and
	 
	 	12.1.2.	 	not use any Restricted Information for any purpose other than the performance of its
obligations under this Agreement.

	12.2.	 	Any Restricted Information may be disclosed by IDIS to:

	 	12.2.1.	 	any customers or prospective customers;
	 
	 	12.2.2.	 	any governmental or other authority or regulatory body where required by law or to
perform its obligation hereunder; or
	 
	 	12.2.3.	 	any employees of IDIS or of any of the aforementioned persons;

to such extent only as is necessary for the purposes contemplated by this Agreement, or as
is required by law and subject in each case to IDIS using its best endeavours to ensure that
the person in question keeps the same confidential and does not use the same except for
the purposes for which the disclosure is made.

	12.3.	 	Any Restricted Information may be used by IDIS for any purpose, or disclosed by IDIS to any
other person, to the extent only that:

	 	12.3.1.	 	it is on the date of this Agreement, or becomes, public knowledge through no fault
of IDIS (provided that in doing so IDIS shall not disclose any Restricted Information which
is not public knowledge); or
	 
	 	12.3.2.	 	it can be shown by IDIS, to the reasonable satisfaction of the Manufacturer, to have
been known to it prior to its being disclosed by the Manufacturer to IDIS.

	13.	 	Force Majeure
	 
	13.1.	 	If either party is affected by Force Majeure it shall forthwith notify the other party of the
nature and extent thereof.
	 
	13.2.	 	Neither party shall be deemed to be in breach of this Agreement, or otherwise be liable to
the other, by reason of any delay in performance, or its non-performance, of any of its obligations
under this Agreement to the extent that such delay or non-performance is due to any Force Majeure
of which it has
notified the other party; and the time for performance of that obligation shall be extended
accordingly.

Page 17 of 33

 

	13.3.	 	If the Force Majeure in question prevails for a continuous period in excess of three months,
the party not affected may terminate this Agreement upon notice to the other.
	 
	14.	 	Notice
	 
	14.1.	 	Any notice to be served by one party on the other shall be in writing and shall be served by
sending it by pre-paid recorded delivery (or by pre-paid registered air mail where appropriate) to
the Service Address or by fax to the Fax Address or to such other address as notified by that party
from time to time.
	 
	14.2.	 	Notice shall be deemed received in the case of: pre-paid recorded delivery, two Business Days
from date of posting; registered airmail, five Business Days from the date of posting; and fax, at
the time of transmission.
	 
	14.3.	 	In proving service it shall be sufficient to prove that the envelope containing such notice
was correctly addressed and delivered or the notice was transmitted by fax to the Fax Address and a
successful transmission sheet exists.
	 
	15.	 	General
	 
	15.1.	 	Neither party shall without the prior written consent of the other sub-contract, assign,
charge or transfer, or purport to sub-contract, assign, charge or transfer to any other person any
of its rights or obligations under this Agreement, or to create a trust thereof, without the prior
written consent of the other party.
	 
	15.2.	 	Except as otherwise specifically provided in this Agreement, neither IDIS nor its agents or
employees shall be deemed to be an agent of the Manufacturer for any purpose whatsoever, and IDIS
shall not have, nor shall it represent itself as having, any authority to make contracts or
obligations in the name of, or binding upon, the Manufacturer, to pledge the Manufacturer’s credit,
or to extend credit to anyone in the Manufacturer’s name. Nothing in this Agreement shall
constitute, or be deemed to constitute, the parties a partnership, association, joint venture or
other co-operative entity.
	 
	15.3.	 	This Agreement, together with the Technical Agreement, contains the entire Agreement between
the parties in respect of the subject matter of the Agreement, and supersedes all previous
Agreements and understandings between the parties with respect thereto. This Agreement may not be
modified except in writing signed by the duly authorised representatives of each party. Neither
party has been induced to enter into this Agreement in reliance upon, nor has either party been
given, any warranty, representation, statement, assurance, covenant, agreement, undertaking,
indemnity or

Page 18 of 33

 

	 	 	commitment of any nature whatsoever other than as expressly set out herein and, to the
extent that it has been, it unconditionally and irrevocably waives any claims, rights or
remedies which it might otherwise have had in relation thereto. Neither party has any right
to rescind or terminate this Agreement either for breach of contract or for negligent or
innocent misrepresentation or otherwise. Nothing in this clause 15.3 shall exclude or limit,
or purport to exclude or limit any liability which either party would otherwise have to the
other or any right which either of them may have in respect of any statements made
fraudulently by either of them prior to the execution of this Agreement or any rights which
either of them may have in respect of fraudulent concealment by the other.
	 
	15.4.	 	In the event that any of the provisions of this Agreement or the application of any such
provisions to the parties shall be held by a court of competent jurisdiction to be contrary to law,
the remaining portions of this Agreement shall remain in full force and effect.
	 
	15.5.	 	No waiver by either party of any breach of this Agreement by the other shall be considered as
a waiver of any subsequent breach of the same or any other provisions.
	 
	15.6.	 	This Agreement may be reproduced in any number of counterparts on each when executed shall be
construed as an original.
	 
	15.7.	 	Neither party shall be liable to the other for any indirect or consequential loss or for any
loss of profits or loss of goodwill which it may suffer even if such loss is reasonably foreseeable
or if it had been advised of the possibility of incurring the same, provided that nothing in this
Agreement shall exclude or limit or purport to exclude or limit any liability which cannot lawfully
be excluded or limited.
	 
	15.8.	 	Save as expressly otherwise provided in this Agreement each of the parties shall bear its own
legal, accountancy and other costs, charges and expenses connected with the negotiation,
preparation and implementation of this Agreement and any other agreement incidental to or referred
to in this Agreement.
	 
	16.	 	Governing Law and Jurisdiction
	 
	 	 	This Agreement (and any dispute, controversy, proceedings or claims arising out of, or in
any way relating to, this Agreement or its formation) shall be governed by and construed in
all respects in accordance with English law, and each party hereby irrevocably submits to
the exclusive
jurisdiction of the courts of England and Wales to hear and decide and/or settle any of the
foregoing.
	 
	17.	 	Third Party Rights

Page 19 of 33

 

	 	 	The Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement and
no rights or benefits expressly or impliedly conferred by it shall be enforceable under
that Act against the parties (or either of them) by any other person.

IN WITNESS of which the parties have signed this Agreement on the date set out above.

	 	 	 	 	 
	 	 	 
	SIGNED for and on behalf of the 	/s/ I. T. Scoular
 	 
	Manufacturer by Ian Scoular 	Director of Business Development 	 
	 	 	 
	 	 	 
	SIGNED for and on behalf of IDIS 	/s/ Natalie Douglas
 	 23 March 2006 
	by Natalie Douglas 	Managing Director 	 
	 	 
	 

Page 20 of 33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]